WALTHAM, Mass.—Fresenius Medical Care and Advanced Renal Technologies have signed an agreement under which Fresenius will supply and distribute Citrasate and DRYalysate in the United States.
The supply and distribution of the products will be handled by Fresenius’ subsidiary Fresenius USA Marketing.
Citrasate uses citric acid, a known anticoagulant, rather than traditional acetic acid, to regulate dialysate pH. Unlike traditional acetic acid, citric acid may provide a local anticoagulant effect at the dialysis membrane during hemodialysis, according to Advanced Renal.
“It is important that Fresenius Medical Care continues to offer technological innovations to our market,” said Rice Powell, co-CEO of Fresenius Medical Care North America. “We constantly strive to provide our renal partners with products and services that provide intradialytic enhancements. Citrasate and DRYalysate may further provide medical benefits and cost savings by reducing the amount of heparin used for anticoagulation. We believe that working with Advanced Renal Technologies to provide a citrate dialysate to the industry is an important step to providing the market with products that may provide superior clinical benefit to traditional therapies utilized today.”
“Currently, Citrasate is mostly used by nurses and nephrologists in the acute market where little to no utilization of heparin is the therapeutic preference,” said Michael Fulton, president of Advanced Renal Technologies. “This agreement will provide nephrologists access to this product when prescribing treatment to patients in chronic hemodialysis facilities nationwide. Many ESRD patients, including those with heparin antibodies and heparin-induced thrombocytopenia, will benefit from Citrasate.”
